Document is current
Any future updates will be listed below
-
Authors
Augustin, Matthias
Serra-Baldrich, Esther
Seneschal, Julien
Grond, Susanne
Lampropoulou, Anastasia
Elrayes, Mohamed
Ogwu, Samuel
de la Torre, Inmaculada
Bewley, Anthony
Pinter, Andreas
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 5 February 2025
First Online: 7 April 2025
Declarations
:
: Matthias Augustin served as a consultant or paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of alopecia areata including AbbVie, Almirall, Eli Lilly and Company, and Pfizer and received support for attending meetings/travel from Eli Lilly and Company. Anthony Bewley reports royalties from Practical Pyschodermatology (Wiley 2014); ad hoc consulting fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, Leo-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; ad hoc lecturing fees from AbbVie, Almirall, BMS, Eli Lilly and Company, Galderma, Incyte, Leo-Pharma, Janssen, Novartis, Pfizer, Sanofi, UCB; support for attending meetings/travel from Novartis, Galderma, UCB, Janssen, Sanofi and other financial or non-financial interests including Immediate Past President of ESDaP, Medical Advisory Board for National Eczema Society, Ichthyosis Support Group and Psoriasis Association. Julien Seneschal reports personal consulting fees from AbbVie, Almirall, Leo-Pharma, Eli Lilly and Company, Pfizer, La Roche Posay; honoraria from AbbVie, Almirall, Leo-Pharma, Eli Lilly and Company, Pfizer. Esther Seera-Baldrich reports payment/honoraria from Amgen, Leo-Pharma, Sanofi, Eli Lilly and Company, Pfizer, Novartis, AbbVie, Incyte, Almirall and Galderma; support for attending meetings/travel from Eli Lilly and Company, Sanofi, Pfizer, Novartis and Leo-Pharma. Andrew Pinter reports payment/honoraria from Eli Lilly and Company; support for attending meetings and/or travel from Eli Lilly and Company and participation on Data Safety Monitoring/Advisory Boards from Eli Lilly and Company. Susanne Grond, Anastasia Lampropoulou, Mohamed Elrayes, Samuel Ogwu and Inmaculada De La Torre are employees and minor shareholders of Eli Lilly and Company.
: Protocols for all studies included in this analysis were approved by the Institutional Review Board or Ethics Committee at each participating site. All studies included in this analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all eligible participants before undergoing study-related procedures.
